세계의 혈액 악성 종양 검사 시장 보고서(2025년)

Hematologic Malignancies Testing Global Market Report 2025

US $ 4,490 ￦ 6,235,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,013,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,790,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

혈액 악성 종양 검사 시장 규모는 향후 몇 년 동안 연평균 13.4%의 성장세를 보이며 2029년에는 59억 4,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 맞춤형 암 치료에 대한 수요 증가, 차세대 시퀀서 보급, 신흥 시장에서의 헬스케어 지출 증가, 정밀 종양학 이니셔티브의 확대, 혈액암 치료에 초점을 맞춘 임상시험의 증가 등입니다. 예상되는 주요 동향으로는 분자 검사 기술의 발전, 자동화 및 고처리량 진단 플랫폼의 개발, 혈액 악성 종양에 대한 지속적인 연구와 혁신, 검사 해석에 인공지능의 통합, 혈액암에 대한 액체 생검법의 획기적인 발전 등을 꼽았습니다.

암 진단 건수의 증가는 향후 몇 년 동안 혈액 악성 종양 검사 시장의 성장을 견인할 것으로 예상됩니다. 암 진단은 영상 검사, 임상 검사, 생검 등 다양한 의학적 검사 및 평가를 통해 환자의 암 유무, 종류, 병기를 확인합니다. 암 진단의 증가는 검진 프로그램에 대한 접근성이 개선되고 일반 대중의 인식이 높아져 조기 발견이 가능해졌기 때문입니다. 혈액 악성 종양 검사는 혈액 관련 암의 조기 발견, 정확한 분류 및 모니터링을 가능하게함으로써 암 진단을 지원하고, 궁극적으로 표적 치료 결정을 유도하여 환자의 예후를 개선할 수 있습니다. 예를 들어, 미국 비영리단체인 미국암협회에 따르면, 2024년 미국에서 새로 암 진단을 받은 환자 수는 200만 명을 넘어 전년 대비 4% 증가할 것으로 예상됩니다. 따라서 암 진단 건수의 증가는 혈액 악성 종양 검사 시장의 성장을 촉진하고 있습니다.

혈액 악성 종양 검사 시장의 주요 기업들은 의료진에게 혈액암의 조기 발견, 치료 계획 및 모니터링을 개선하는 정확하고 시기적절한 진단 도구를 제공하기 위해 신속 분자 프로파일링과 같은 혁신적인 진단 방법에 집중하고 있습니다. 신속 분자 프로파일링은 환자의 유전자 프로파일을 분석하여 돌연변이 및 변이를 식별하는 진단 기술로, 보다 신속하고 개별화된 치료 방침을 결정할 수 있게 해줍니다. 예를 들어, 2023년 11월 미국 암센터인 로즈웰파크 종합암센터는 백혈병, 림프종, 다발성 골수종 등 혈액암을 보다 정확하고 빠르게 진단할 수 있도록 설계된 차세대 유전자 염기서열 분석 도구인 판헴(PanHeme)을 발표하였습니다. 이 검사는 72시간 내에 수백 개의 유전자 돌연변이를 검출하여 진단의 속도와 정확성을 크게 향상시켜 보다 맞춤화된 치료 계획을 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 혈액 악성 종양 검사 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 혈액 악성 종양 검사 시장 : 성장률 분석
• 세계의 혈액 악성 종양 검사 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 혈액 악성 종양 검사 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 혈액 악성 종양 검사 전체 시장(TAM)

제6장 시장 세분화

• 세계의 혈액 악성 종양 검사 시장 : 테스트 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 전혈구수(CBC)
• 유세포 분석
• 분자 검사
• 유전자 검사
• 기타 테스트 종류
• 세계의 혈액 악성 종양 검사 시장 : 제품별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 키트
• 서비스
• 세계의 혈액 악성 종양 검사 시장 : 기술별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 중합효소 연쇄 반응(PCR)
• 차세대 시퀀싱(NGS)
• 면역조직화학(IHC)
• 세포유전학
• 기타 기술
• 세계의 혈액 악성 종양 검사 시장 : 치료 적응증별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 백혈병
• 림프종
• 다발성 골수종
• 골수 증식성 종양
• 기타 치료 적응증
• 세계의 혈액 악성 종양 검사 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 진단 실험실
• 학술조사기관
• 기타 최종사용자
• 세계의 혈액 악성 종양 검사 시장, 전혈구 산정(CBC) 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 헤모글로빈 검사
• 헤마토크릿 측정
• 백혈구수
• 적혈구수
• 혈소판수
• 평균 적혈구 용적(MCV)
• 평균 적혈구 헤모글로빈(MCH)
• 세계의 혈액 악성 종양 검사 시장, 유세포 분석 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 면역 표현형 검사
• 세포 주기 분석
• 아포토시스 검출
• 미세잔존질환(MRD) 검사
• DNA 함유량 분석
• 세계의 혈액 악성 종양 검사 시장, 분자 검사 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 중합효소 연쇄 반응(PCR)
• 차세대 시퀀싱(NGS)
• 역전사 PCR(RT-PCR)
• FISH(Fluorescent In Situ Hybridization)
• 마이크로어레이 해석
• 세계의 혈액 악성 종양 검사 시장, 유전자 검사 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 생식세포 변이 검사
• 체세포 변이 검사
• 세포유전학적 검사
• 염색체 이상 검출
• 단일염기다형(SNP) 해석
• 세계의 혈액 악성 종양 검사 시장, 기타 테스트 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 골수 생검
• 면역조직화학(IHC)
• 효소 어세이
• 혈청 단백질 전기영동(SPEP)
• 영상 검사

제7장 지역별·국가별 분석

• 세계의 혈액 악성 종양 검사 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 혈액 악성 종양 검사 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 혈액 악성 종양 검사 시장 : 경쟁 구도
• 혈액 악성 종양 검사 시장 : 기업 개요
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Abbott Laboratories
• Novartis Aktiengesellschaft
• GlaxoSmithKline Public Limited Company
• Eli Lilly and Company
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Sun Pharmaceutical Industries Limited
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Invitae Corporation
• Adaptive Biotechnologies Corporation
• Invivoscribe Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 혈액 악성 종양 검사 시장 2029년 : 새로운 기회를 제공하는 국가
• 혈액 악성 종양 검사 시장 2029년 : 새로운 기회를 제공하는 부문
• 혈액 악성 종양 검사 시장 2029년 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Hematologic malignancies testing involves diagnostic and monitoring procedures aimed at detecting, classifying, and assessing cancers of the blood, bone marrow, and lymphatic system. This testing provides precise identification of the type and subtype of malignancy, helps determine prognosis, informs treatment strategies, and tracks treatment response or disease relapse.

The primary types of tests for hematologic malignancies include complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and other methods. A complete blood count (CBC) measures various blood components such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Products in this area are classified as kits and services. Technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, among others. These tests address therapeutic indications like leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and more. They are utilized by a range of end-users including hospitals, diagnostic laboratories, academic institutions, research centers, and others.

The hematologic malignancies testing market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies testing market statistics, including the hematologic malignancies testing industry global market size, regional shares, competitors with the hematologic malignancies testing market share, detailed hematologic malignancies testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. This hematologic malignancies testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to an increasing incidence of blood cancers, heightened awareness of early cancer detection, expanded use of flow cytometry and molecular diagnostics, growth in hematology testing across hospitals and laboratories, and improved availability of reimbursement for cancer diagnostic procedures.

The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period is driven by increasing demand for personalized cancer treatments, wider adoption of next-generation sequencing, rising healthcare expenditures in emerging markets, expansion of precision oncology initiatives, and a growing number of clinical trials focused on blood cancer therapies. Key trends expected include advancements in molecular testing technologies, the development of automated and high-throughput diagnostic platforms, ongoing research and innovation in hematologic malignancies, integration of artificial intelligence in test interpretation, and breakthroughs in liquid biopsy methods for blood cancers.

The increasing number of cancer diagnoses is expected to drive the growth of the hematologic malignancies testing market in the coming years. Cancer diagnosis involves identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rise in cancer diagnoses is attributed to improved access to screening programs and greater public awareness, leading to earlier detection. Hematologic malignancies testing supports cancer diagnosis by enabling early detection, accurate classification, and monitoring of blood-related cancers, which ultimately helps guide targeted treatment decisions and improves patient outcomes. For example, according to the American Cancer Society, a US-based nonprofit organization, over 2 million new cancer cases were diagnosed in the US in 2024, marking a 4% increase from previous years. Therefore, the rising number of cancer diagnoses is driving growth in the hematologic malignancies testing market.

Leading companies in the hematologic malignancies testing market are focusing on innovative diagnostic methods, such as rapid molecular profiling, to provide healthcare professionals with precise and timely diagnostic tools that improve early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic technique that analyzes a patient's genetic profile to identify mutations and variations, allowing for faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. This test detects mutations in hundreds of genes within 72 hours, significantly enhancing the speed and precision of diagnosis and supporting more personalized treatment plans.

In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology firm specializing in hematologic malignancies testing, partnered with NeoGenomics Laboratories, Inc. to expand personalized disease monitoring for blood cancer patients. Through this collaboration, Adaptive Biotechnologies and NeoGenomics aim to broaden access to precise minimal residual disease monitoring in blood cancers by incorporating the clonoSEQ test into NeoGenomics' diagnostic services, thereby improving treatment decisions and disease tracking. NeoGenomics Laboratories Inc. is a US-based public, high-complexity clinical laboratory specializing in cancer genetics diagnostic testing.

Major players in the hematologic malignancies testing market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Aktiengesellschaft, Merck & Co. Inc., Bayer Aktiengesellschaft, AstraZeneca PLC, Abbott Laboratories, Novartis Aktiengesellschaft, GlaxoSmithKline Public Limited Company, Eli Lilly and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sun Pharmaceutical Industries Limited, Illumina Inc., Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Invitae Corporation, Adaptive Biotechnologies Corporation, Invivoscribe Inc.

North America was the largest region in the hematologic malignancies testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hematologic malignancies testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hematologic malignancies testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hematologic Malignancies Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hematologic malignancies testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hematologic malignancies testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Complete Blood Count (CBC); Flow Cytometry; Molecular Testing; Genetic Testing; Others Test Type
• 2) By Product: Kits; Services
• 3) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Immunohisto Chemistry (IHC); Cytogenetics; Others Technology
• 4) By Therapeutic Indication: Leukemia; Lymphoma; Multiple Myeloma; Myeloproliferative Neoplasms; Others Therapeutic Indication
• 5) By End User: Hospitals; Diagnostic Labs; Academic and Research Institutions; Others End Users
• Subsegments:
• 1) By Complete Blood Count (CBC): Hemoglobin Testing; Hematocrit Measurement; White Blood Cell Count; Red Blood Cell Count; Platelet Count; Mean Corpuscular Volume (MCV); Mean Corpuscular Hemoglobin (MCH)
• 2) By Flow Cytometry: Immunophenotyping; Cell Cycle Analysis; Apoptosis Detection; Minimal Residual Disease (MRD) Testing; DNA Content Analysis
• 3) By Molecular Testing: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Reverse Transcriptase-PCR (RT-PCR); Fluorescence In Situ Hybridization (FISH); Microarray Analysis
• 4) By Genetic Testing: Germline Mutation Testing; Somatic Mutation Testing; Cytogenetic Testing; Chromosomal Aberration Detection; Single Nucleotide Polymorphism (SNP) Analysis
• 5) By Others Test Type: Bone Marrow Biopsy; Immunohistochemistry (IHC); Enzyme Assays; Serum Protein Electrophoresis (SPEP); Imaging Tests
• Companies Mentioned: Johnson & Johnson Private Limited; F. Hoffmann-La Roche Aktiengesellschaft; Merck & Co. Inc.; Bayer Aktiengesellschaft; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hematologic Malignancies Testing Market Characteristics

3. Hematologic Malignancies Testing Market Trends And Strategies

4. Hematologic Malignancies Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hematologic Malignancies Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hematologic Malignancies Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hematologic Malignancies Testing Market Growth Rate Analysis
• 5.4. Global Hematologic Malignancies Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hematologic Malignancies Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hematologic Malignancies Testing Total Addressable Market (TAM)

6. Hematologic Malignancies Testing Market Segmentation

• 6.1. Global Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Blood Count (CBC)
• Flow Cytometry
• Molecular Testing
• Genetic Testing
• Others Test Type
• 6.2. Global Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kits
• Services
• 6.3. Global Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Immunohisto Chemistry (IHC)
• Cytogenetics
• Others Technology
• 6.4. Global Hematologic Malignancies Testing Market, Segmentation By Therapeutic Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Others Therapeutic Indication
• 6.5. Global Hematologic Malignancies Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Labs
• Academic And Research Institutions
• Others End Users
• 6.6. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Complete Blood Count (CBC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Testing
• Hematocrit Measurement
• White Blood Cell Count
• Red Blood Cell Count
• Platelet Count
• Mean Corpuscular Volume (MCV)
• Mean Corpuscular Hemoglobin (MCH)
• 6.7. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Flow Cytometry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunophenotyping
• Cell Cycle Analysis
• Apoptosis Detection
• Minimal Residual Disease (MRD) Testing
• DNA Content Analysis
• 6.8. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Molecular Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Reverse Transcriptase-PCR (RT-PCR)
• Fluorescence In Situ Hybridization (FISH)
• Microarray Analysis
• 6.9. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Genetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Germline Mutation Testing
• Somatic Mutation Testing
• Cytogenetic Testing
• Chromosomal Aberration Detection
• Single Nucleotide Polymorphism (SNP) Analysis
• 6.10. Global Hematologic Malignancies Testing Market, Sub-Segmentation Of Others Test Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Marrow Biopsy
• Immunohistochemistry (IHC)
• Enzyme Assays
• Serum Protein Electrophoresis (SPEP)
• Imaging Tests

7. Hematologic Malignancies Testing Market Regional And Country Analysis

• 7.1. Global Hematologic Malignancies Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hematologic Malignancies Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hematologic Malignancies Testing Market

• 8.1. Asia-Pacific Hematologic Malignancies Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hematologic Malignancies Testing Market

• 9.1. China Hematologic Malignancies Testing Market Overview
• 9.2. China Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hematologic Malignancies Testing Market

• 10.1. India Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hematologic Malignancies Testing Market

• 11.1. Japan Hematologic Malignancies Testing Market Overview
• 11.2. Japan Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hematologic Malignancies Testing Market

• 12.1. Australia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hematologic Malignancies Testing Market

• 13.1. Indonesia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hematologic Malignancies Testing Market

• 14.1. South Korea Hematologic Malignancies Testing Market Overview
• 14.2. South Korea Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hematologic Malignancies Testing Market

• 15.1. Western Europe Hematologic Malignancies Testing Market Overview
• 15.2. Western Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hematologic Malignancies Testing Market

• 16.1. UK Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hematologic Malignancies Testing Market

• 17.1. Germany Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hematologic Malignancies Testing Market

• 18.1. France Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hematologic Malignancies Testing Market

• 19.1. Italy Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hematologic Malignancies Testing Market

• 20.1. Spain Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hematologic Malignancies Testing Market

• 21.1. Eastern Europe Hematologic Malignancies Testing Market Overview
• 21.2. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hematologic Malignancies Testing Market

• 22.1. Russia Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hematologic Malignancies Testing Market

• 23.1. North America Hematologic Malignancies Testing Market Overview
• 23.2. North America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hematologic Malignancies Testing Market

• 24.1. USA Hematologic Malignancies Testing Market Overview
• 24.2. USA Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hematologic Malignancies Testing Market

• 25.1. Canada Hematologic Malignancies Testing Market Overview
• 25.2. Canada Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hematologic Malignancies Testing Market

• 26.1. South America Hematologic Malignancies Testing Market Overview
• 26.2. South America Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hematologic Malignancies Testing Market

• 27.1. Brazil Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hematologic Malignancies Testing Market

• 28.1. Middle East Hematologic Malignancies Testing Market Overview
• 28.2. Middle East Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hematologic Malignancies Testing Market

• 29.1. Africa Hematologic Malignancies Testing Market Overview
• 29.2. Africa Hematologic Malignancies Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hematologic Malignancies Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hematologic Malignancies Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hematologic Malignancies Testing Market Competitive Landscape And Company Profiles

• 30.1. Hematologic Malignancies Testing Market Competitive Landscape
• 30.2. Hematologic Malignancies Testing Market Company Profiles
  • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Hematologic Malignancies Testing Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis Aktiengesellschaft
• 31.3. GlaxoSmithKline Public Limited Company
• 31.4. Eli Lilly and Company
• 31.5. Laboratory Corporation of America Holdings
• 31.6. Agilent Technologies Inc.
• 31.7. Sun Pharmaceutical Industries Limited
• 31.8. Illumina Inc.
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. Cipla Limited
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Lupin Limited
• 31.13. Invitae Corporation
• 31.14. Adaptive Biotechnologies Corporation
• 31.15. Invivoscribe Inc.

32. Global Hematologic Malignancies Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hematologic Malignancies Testing Market

34. Recent Developments In The Hematologic Malignancies Testing Market

35. Hematologic Malignancies Testing Market High Potential Countries, Segments and Strategies

• 35.1 Hematologic Malignancies Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hematologic Malignancies Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hematologic Malignancies Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료